SCHEMBL3076922

SCHEMBL3076922

CC(C)(C)NC(=O)c1cc(N)cc(N)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
APEX1 P27695 1/20 0.44
JAK2 O60674 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.39
IMPDH2 P12268 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38
HPGDS O60760 1/20 0.38
MAOB P27338 1/20 0.37
AOC3 Q16853 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13139932 0.96 JAK2 (0.43) POLBAPEX1JAK2MEN1KMT2A
SCHEMBL21198754 0.87 ANO1 (0.43) POLBAPEX1JAK2MEN1KMT2A
SCHEMBL570284 0.84 MEN1 (0.49) POLBAPEX1JAK2MEN1KMT2A
SCHEMBL3043953 0.81 ALDH1A1 (0.54) POLBKMT2ALMNAHTTSMN1; SMN2
SCHEMBL4817141 0.81 TPMT (0.48) POLBAPEX1MEN1KMT2ALMNA
SCHEMBL3079819 0.80 POLB (0.60) POLBMEN1KMT2AMAPTHTT
Hydrochloric Acid SCHEMBL21198410 0.80 ALDH1A1 (0.53) POLBKMT2ALMNAHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL31306628 0.80 ALDH1A1 (0.53) POLBKMT2ALMNAHTTSMN1; SMN2
SCHEMBL18285300 0.79 TP53 (0.49) POLBJAK2LMNA
SCHEMBL18285282 0.79 JAK2 (0.45) JAK2LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592738-B1 RESIN COMPOSITIONS CIBA HOLDING INC (CH) 2020-07-29 EP disclosed
US-7790793-B2 Amide nucleating agent compositions CIBA SPECIALTY CHEM. CORP. (US) 2010-09-07 US disclosed
CN-100344681-C Resin compositions CIBA SC HOLDING AG (CH) 2007-10-24 CN disclosed
US-20070149663-A1 Resin compositions CIBA SPECIALTY CHEMICALS CORP. 2007-06-28 US disclosed
US-20060100461-A1 Acetamidobenzamide compounds for neurodegenerative disorders RENOVIS, INC. 2006-05-11 US disclosed
CN-1747995-A Resin compositions CIBA SC HOLDING AG (CH) 2006-03-15 CN disclosed
US-7005546-B2 Acetamidobenzamide compounds for neurodegenerative disorders RENOVIS, INC. (US) 2006-02-28 US disclosed
EP-1592738-A2 RESIN COMPOSITIONS Ciba SC Holding AG (CH) 2005-11-09 EP disclosed
EP-1581202-A2 METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME Renovis, Inc. (US) 2005-10-05 EP disclosed
US-20040266881-A1 Acetamidobenzamide compounds for neurodegenerative disorders RENOVIS, INC. 2004-12-30 US disclosed
US-6077870-A ACETAMIDOBENZAMIDE COMPOUNDS EXHIBIT STRONG ACTIVITY AGAINST PARKINSON'S DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 2000-06-20 US disclosed
US-6066765-A METHOD OF MAKING 4-ACETAMIDOBENZAMIDE COMPOUNDS OF GIVEN FORMULA BY CONDENSING AN ALKYLAMINE WITH A 4-NITROBENZOYL HALIDE TO PRODUCE A 4-NITROBENZAMIDE, REDUCING THE NITRO GROUP AND ACETYLATING THE AMINO GROUP CENTAUR PHARMACEUTICALS, INC. (US) 2000-05-23 US disclosed
US-5914350-A TREATING PARKINSON*S DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 1999-06-22 US disclosed
US-5907061-A AMIDATION A NITROBENZOYLHALIDE WITH A SATURATED ALKYLAMINE TO FORM A DRUG TREATING PARKINSON'S DISEASE OR SLOW THE PROGRESSIVE LOSS OF FUNCTION CENTAUR PHARMACEUTICALS, INC. (US) 1999-05-25 US disclosed
EP-0912171-A1 BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION CENTAUR PHARMACEUTICALS, INC. (US) 1999-05-06 EP disclosed
US-5756548-A TREATMENT OF PARKINSON*S DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 1998-05-26 US disclosed
WO-1997038684-A1 BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION CENTAUR PHARMACEUTICALS, INC. (US) 1997-10-23 WO disclosed
US-5659082-A Nitro- and aminobenzamide compounds for neurodegenerative disorders CENTAUR PHARMACEUTICALS, INC. (US) 1997-08-19 US disclosed
US-5658953-A Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders CENTAUR PHARMACEUTICALS, INC. (US) 1997-08-19 US disclosed
US-5643965-A TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS CENTAUR PHARMACEUTICALS, INC. (US) 1997-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266881-A1 Acetamidobenzamide compounds for neurodegenerative disorders SNCA, PARK7, GBA1 POLB 468/4885APEX1 3313/4885JAK2 4128/4885
US-20060100461-A1 Acetamidobenzamide compounds for neurodegenerative disorders SNCA, PARK7, GBA1 POLB 468/4885APEX1 3313/4885JAK2 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.